Open AccessS129: TAKEAIM LEUKEMIA‐ A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA‐4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
Author(s) -
GarciaManero G.,
Winer E. S.,
DeAngelo D. J.,
Tarantolo S.,
Sallman D. A.,
Dugan J.,
Groepper S.,
Giagounidis A.,
Götze K.,
Metzeler K. H.,
Li C.C.,
Zhou L.,
Martinez E.,
Lane M.,
Roemeling R.,
Bohme M.,
Kubasch A. S.,
Verma A.,
Platzbecker U.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843408.31385.3f
Subject(s) - medicine , azacitidine , venetoclax , oncology , myelodysplastic syndromes , cancer , leukemia , phases of clinical research , clinical trial , chronic lymphocytic leukemia , bone marrow , biology , biochemistry , gene expression , dna methylation , gene